Table 3.
Baseline neutrophil count, lymphocyte count, and neutrophil-to-lymphocyte ratio as predictors of mortality after adjustment for baseline and clinical covariables in GENISOS cohort
| Neutrophil | Lymphocyte | NLR* | ||||
|---|---|---|---|---|---|---|
| Characteristic | HR [95% CI] |
P-value | HR [95% CI] |
P-value | HR [95% CI] |
P-value |
| Baseline count or ratio | 1.47 [1.07, 2.03] |
0.017 | 0.69 [0.50, 0.93] |
0.016 | 1.48 [1.18, 1.84] |
0.001 |
| Male gender | 1.14 [0.69, 1.89] |
0.604 | 1.15 [0.69, 1.90] |
0.595 | 1.03 [0.62, 1.73] |
0.902 |
| Age at enrollment | 1.03 [1.01, 1.05] |
<0.001 | 1.03 [1.01, 1.05] |
0.001 | 1.03 [1.01, 1.05] |
0.001 |
| Race | 0.016 | 0.027 | 0.010 | |||
| African American† | 1.83 [1.10, 3.05] |
0.021 | 1.71 [1.03, 2.84] |
0.039 | 1.97 [1.18, 3.30] |
0.009 |
| Latino† | 1.49 [0.89, 2.51] |
0.133 | 1.45 [0.86, 2.43] |
0.165 | 1.48 [0.88, 2.50] |
0.137 |
| Other† | 0.16 [0.02, 1.19] |
0.074 | 0.16 [0.02, 1.19] |
0.074 | 0.17 [0.02, 1.23] |
0.079 |
| Anti-centromere antibody | 0.94 [0.42, 2.10] |
0.875 | 0.95 [0.42, 2.14] |
0.910 | 1.01 [0.45, 2.28] |
0.979 |
| Baseline mRSS | 1.00 [0.98, 1.02] |
0.846 | 1.00 [0.99, 1.02] |
0.692 | 1.00 [0.98, 1.02] |
0.908 |
| Baseline FVC% | 0.97 [0.96, 0.98] |
<0.001 | 0.97 [0.96, 0.98] |
<0.001 | 0.97 [0.96, 0.98] |
<0.001 |
| Baseline prednisone use ∮ | 1.27 [0.61, 2.62] |
0.521 | 1.35 [0.66, 2.77] |
0.416 | 1.17 [0.56, 2.43] |
0.677 |
Analysis by multivariable Cox proportional hazards model
*
Neutrophil-to-lymphocyte ratio
†
Compared to White patients
∮
Prednisone dose greater than 10 mg per day